Fast Profits, Smart Plays! Pre-Market Guide

Don’t want emails from us anymore? Click here to unsubscribe

Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

  • Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

  • Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

  • Top Pre-Market Movers: Identify early winners poised for a strong market opening.

  • Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

  • FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.


$200 Trillion "AI Phase 2" Moments Away?

"AI Phase 2" is on course to mint 2,931 millionaires every single day...

And if you click here now, you'll see how YOU could get a piece of the action...

Happening Today

✓ 08:30 AM ET – GDP (QoQ) (Q4)

✓ 08:30 AM ET – Initial Jobless Claims

✓ 09:45 AM ET – Chicago PMI (Mar)

✓ 10:00 AM ET – Michigan 5-Year Inflation Expectations (Mar)


Among major indexes, Dow Jones takes the crown with a 1.22% daily gain.



⬆️ 0.86% 



⬆️ 1.22%



⬆️ 0.51%


While most sectors gained today, Utilities (+2.75%) were the star performer.




Consumer Discretionary


+1.10% 🟢

Consumer Staples


+0.96% 🟢



+0.94% 🟢



+1.22% 🟢

Health Care


+1.30% 🟢



+1.60% 🟢



+1.44% 🟢

Real Estate


+2.42% 🟢

Information Technology


+0.12% 🟢

Communication Services


+0.11% 🟢



+2.75% 🟢


Yours Free: My Top 7 Election Year Stocks

With the 2024 election barreling toward us, now is the time to prepare your portfolio.

All signs point to another nasty election cycle that looks too close to call. So the best strategy now is to own stocks that have a strong history of post-election gains no matter which party wins. We've pinpointed 7 stocks that do just that.

Get their names free time in our new report, "7 Stocks to Own Before the 2024 Election."

Unusual Volume

📈 iBio Inc (IBIO) jumped 192.17% to $3.36 on a whopping 170.42 million shares traded after it announced that it has entered into a collaboration agreement with AstralBio, Inc. to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.

📈 Investors went wild, sending Verb Technology Company Inc (VERB) stock soaring 0.36% to $0.28 on a massive volume of 129.66 million shares after the company released that it has entered into a formal partnership with TikTok Shop pursuant to which has become a service provider for TikTok Shop and is officially designated as a TikTok Shop Partner (TSP).

📈 Abnormal activity shook Gamida Cell Ltd (GMDA), pushing it down -82.74% to $0.06 on a whopping 125.55 million shares traded. This decrease followed news that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.

📈 Canopy Growth Corporation (CGC) stock recently closed 32.09% upper at $9.55 on substantial volume of 53.25 million shares.

📈 Trump Media & Technology Group Corp. (DJT) increase by 14.19% in a single trading session, with abnormally high trading volume of 32.59 million shares.


Revealed - the AI Stock that's Disrupting Every Industry

With so many AI stocks out there, finding those worthy of investment can be confusing (and time consuming). Here's one that's definitely worth a look.

Get this AI Stock Ticker Now!

Premarket Movers

Kintara Therapeutics, Inc. (KTRA) experiences a substantial 21.79% surge in pre-market trading after announcing expansion of REM-001 clinical study to include patients on Pembrolizumab.

Akebia Therapeutics, Inc. (AKBA) sees a significant 14.28% increase, reaching a pre-market price of $2.56 after receiving FDA approval of Vafseo® (vadadustat) tablets for the treatment of Anemia due to chronic kidney disease in adult patients on dialysis.

SRIVARU Holding Limited (SVMH)demonstrates a noteworthy 11.32% surge, with a pre-market price of $0.29. The company announced that it has successfully completed on-road driving range tests of the Company’s new Prana 2.0 intelligent battery system.

Pre Market Gainers

Pre Market Change

Pre Market Volume
































I love this overnight trade happening Thursday

I call these trades 'live lottos' as they're options trades I open on Thursday that expire on Friday. We're not going nuts here. We're putting in as little as $50 and hope to hit 300%... even 1,000% wins in 1 day like I've done with Nvidia and Amazon. They don't win every time, but it's fun when they hit. Discover how I find these trades in my new free presentation.

Access my free presentation on these overnight trades right here

Important FDA 

Recently Announced

Akebia Therapeutics, Inc. (AKBA) receives FDA approval for Vadadustat, a potential treatment for anemia in adult chronic kidney disease patients on dialysis.  

Merck & Co Inc. (MRK) celebrates FDA approval for Sotatercept, now known as WINREVAIR, for pulmonary arterial hypertension in adults. Following successful BLA submission, this approval highlights Merck's commitment to cardiovascular health innovation, offering hope to patients with this debilitating condition.

Orchard Therapeutics plc (ORTX) achieves FDA approval for Lenmeldy, formerly known as OTL-200, for treating metachromatic leukodystrophy in children. With previous approvals in other countries, this milestone underscores Orchard's dedication to advancing gene therapy for rare genetic disorders, bringing new hope to affected families.

Upcoming Announcements

VANDA PHARMACEUTICALS (VNDA) awaits the FDA decision on the expanded use of Fanapt for treating bipolar I disorder in adults, scheduled for April 2, 2024. This pending decision marks a crucial moment for VANDA as it seeks to broaden the therapeutic options for individuals battling this challenging mental health condition.

Legend Biotech Corporation (LEGN) anticipates the FDA decision on expanding the use of Carvykti for earlier treatment of patients with relapsed or refractory multiple myeloma, slated for April 5, 2024. This pending decision holds significant promise for patients and the company alike, as it seeks to enhance treatment options and improve outcomes for individuals with this challenging hematological malignancy.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Bullseye Trades Get free daily HOT STOCK & Options trading ideas with real-money 💰 TRADE ALERTS from trading genius, Jeff Bishop
BraVoCycles NewsletterMarket Timing and Price Projections

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

 Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.